May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
SiRNA in the Treatment of Ocular Hypertension Targeting Alpha and Beta Adrenoceptors
Author Affiliations & Notes
  • J.J. Pintor
    Univ. Complutense de Madrid, Madrid, Spain
    Bioquimica Biologia Molecular IV,
  • A. Mediero
    Bioquimica Biologia Molecular IV, Univ. Computense de Madrid, Madrid, Spain
  • A. Jimenez
    Genomica, Madrid, Spain
  • A. Sesto
    Genomica, Madrid, Spain
  • G. Gonzalez de Buitrago
    Genomica, Madrid, Spain
  • A. Peral
    Univ. Complutense de Madrid, Madrid, Spain
    Optica II (Optometria & Vision),
  • Footnotes
    Commercial Relationships  J.J. Pintor, Genomica, F; A. Mediero, None; A. Jimenez, Genomica, E; A. Sesto, Genomica, E; G. Gonzalez de Buitrago, Genomica, E; A. Peral, Genomica, F.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 403. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.J. Pintor, A. Mediero, A. Jimenez, A. Sesto, G. Gonzalez de Buitrago, A. Peral; SiRNA in the Treatment of Ocular Hypertension Targeting Alpha and Beta Adrenoceptors . Invest. Ophthalmol. Vis. Sci. 2006;47(13):403.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To study the effect of siRNA topical administration against α and ß adrenoceptors on intraocular pressure in New Zealand White rabbits to find a treatment for ocular hypertension and glaucoma.

Methods: : We have designed siRNA for the following adrenergic receptor genes: ß1 (1 siRNA, 007), ß2 (2 siRNA, 012 and 011), α1A (1 siRNA, 097) and α1B (2 siRNA, 99 and 100). siRNAs were administered in saline solution (0.9% w/v) to a final volume of 40µl in one eye during four consecutive days and the opposite eye was taken as a control applying 40µl of sterile saline (0.9% w/v). With the ß2 (012), we did a re–application dose assay, in which we applied twice the protocol mentioned before with a resting day between them.

Results: : The 007 siRNA for ß1 (n=2) reduced IOP in 28.04 ± 2.98 % during 98 hours. ß2/012 siRNA (n=3) caused a decrease in IOP of 21.81 ± 1.55 % (being the control of IOP 100%), lasting 100 hours. ß2/012 gen re–application (n=1) caused a similar decrease in IOP (19.29 ± 0.89 %), lasting 223 hours. ß2/011 siRNA (n=2) did not have the same effect as ß2/012 gen. It produced a decrease in IOP of 14.90 ± 1.26 % during 22 hours. siRNA for α1A (097) (n=2) produced a decrease of 19.08 ± 2.04 % during 93 hours. Moreover, the two different siRNA for α1B (99 and 100) (n=2 each) produced a similar decrease in IOP (17.34 ± 2.26 % for 99 and 14.39 ± 1.49 % for siRNA 100), lasting from 74 hours (for 99) to 78 hours (for 100). As a control of IOP reduction we used Xalatan, which reduced IOP 23.40 ± 2.36 % during 5 to 6 hours.

Conclusions: : The reduction of IOP with siRNA against α and ß adrenoceptors is comparable with those produced by commercial products. Moreover, siRNA have the advantage of presenting a long lasting effect compared to commercial pharmaceutical products.

Keywords: intraocular pressure • gene transfer/gene therapy • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×